Evidence map›Paper›PMID 32938820›Full record

ArticleKidney research and clinical practice2020

Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement.

Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon, Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Current Understanding of Pressure Natriuresis.Electrolyte & blood pressure : E & BP · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Tae Jung OhDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-5078-6123
Ju-Young MoonDivision of Nephrology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-3244-8371
Kyu Yeon HurDivision of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-3065-7252
Seung Hyun KoDivision of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0003-3703-1479
Hyun Jung KimDepartment of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-9520-1109
Taehee KimDivision of Nephrology, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University School of Medicine, Busan, Republic of Korea.ORCID https://orcid.org/0000-0002-3001-234X
Dong Won LeeDivision of Nephrology, Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.ORCID https://orcid.org/0000-0003-0282-484X
Min Kyong MoonDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-5460-2846
Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology
Seoul National University · KRInje University Busan Paik Hospital · KRKorea University · KRKyung Hee University · KRPusan National University · KRSamsung Medical Center · KRThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodiumglucose cotransporter-2 (SGLT2) inhibitors showed profound reno-protective effects. The Korean Diabetes Association and the Korean Society of Nephrology reviewed clinical trials and performed a meta-analysis to assess the effects of SGLT2 inhibitors on the preservation of estimated glomerular filtration rate (eGFR). We limited the data of SGLT2 inhibitors which can be prescribed in Korea. Both eGFR value and its change from the baseline were significantly more preserved in the SGLT2-inhibitor treatment group compared to the control group after 156 weeks. However, some known adverse events were increased in SGLT2 inhibitor treatment, such as genital infection, diabetic ketoacidosis, and volume depletion. We recommend long-term use of SGLT2 inhibitors in patients with type 2 diabetes mellitus (T2DM) for attenuation of renal function decline. However, we cannot generalize our recommendations due to the lack of long-term clinical trials testing the reno-protective effects of every SGLT2 inhibitor in a broad range of patients with T2DM. This recommendation can be revised and updated after the publication of several large-scale renal outcome trials.

Indexed as

Diabetes mellitusGlomerular filtration rateRenal functionSodium-glucose transporter-2 inhibitorstype 2

Identifiers

PMID32938820
PMCPMC7530358
OpenAlexW3113112097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.